vs
Apellis Pharmaceuticals, Inc.（APLS）与STONERIDGE INC（SRI）财务数据对比。点击上方公司名可切换其他公司
STONERIDGE INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$205.2M vs $199.9M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -6.0%），STONERIDGE INC自由现金流更多（$2.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -7.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Stoneridge Inc是全球领先的电气电子元件、集成系统及传感器解决方案设计制造商，服务汽车、商用车、非道路设备与航空航天领域，产品可提升车辆安全性、运行效率、互联性与环保表现，业务覆盖全球核心市场。
APLS vs SRI — 直观对比
营收规模更大
SRI
是对方的1.0倍
$199.9M
营收增速更快
APLS
高出0.1%
-6.0%
自由现金流更多
SRI
多$16.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
-7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $205.2M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 16.2% |
| 营业利润率 | -25.6% | -14.4% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -6.0% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-2.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSRI
| Q4 25 | $199.9M | $205.2M | ||
| Q3 25 | $458.6M | $210.3M | ||
| Q2 25 | $178.5M | $228.0M | ||
| Q1 25 | $166.8M | $217.9M | ||
| Q4 24 | $212.5M | $218.2M | ||
| Q3 24 | $196.8M | $213.8M | ||
| Q2 24 | $199.7M | $237.1M | ||
| Q1 24 | $172.3M | $239.2M |
净利润APLSSRI
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-9.4M | ||
| Q2 25 | $-42.2M | $-9.4M | ||
| Q1 25 | $-92.2M | $-7.2M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-7.1M | ||
| Q2 24 | $-37.7M | $2.8M | ||
| Q1 24 | $-66.4M | $-6.1M |
毛利率APLSSRI
| Q4 25 | — | 16.2% | ||
| Q3 25 | — | 20.3% | ||
| Q2 25 | — | 21.5% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 22.7% | ||
| Q1 24 | — | 20.2% |
营业利润率APLSSRI
| Q4 25 | -25.6% | -14.4% | ||
| Q3 25 | 48.7% | -1.6% | ||
| Q2 25 | -18.6% | -1.1% | ||
| Q1 25 | -50.0% | -1.5% | ||
| Q4 24 | -12.3% | -2.0% | ||
| Q3 24 | -24.0% | 0.1% | ||
| Q2 24 | -14.7% | 1.4% | ||
| Q1 24 | -36.0% | 0.1% |
净利率APLSSRI
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -4.5% | ||
| Q2 25 | -23.6% | -4.1% | ||
| Q1 25 | -55.3% | -3.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -3.3% | ||
| Q2 24 | -18.9% | 1.2% | ||
| Q1 24 | -38.5% | -2.6% |
每股收益（稀释后）APLSSRI
| Q4 25 | $-0.40 | $-2.76 | ||
| Q3 25 | $1.67 | $-0.34 | ||
| Q2 25 | $-0.33 | $-0.34 | ||
| Q1 25 | $-0.74 | $-0.26 | ||
| Q4 24 | $-0.30 | $-0.22 | ||
| Q3 24 | $-0.46 | $-0.26 | ||
| Q2 24 | $-0.30 | $0.10 | ||
| Q1 24 | $-0.54 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $66.3M |
| 总债务越低越好 | — | $180.9M |
| 股东权益账面价值 | $370.1M | $179.8M |
| 总资产 | $1.1B | $551.2M |
| 负债/权益比越低杠杆越低 | — | 1.01× |
8季度趋势，按日历期对齐
现金及短期投资APLSSRI
| Q4 25 | $466.2M | $66.3M | ||
| Q3 25 | $479.2M | $54.0M | ||
| Q2 25 | $370.0M | $49.8M | ||
| Q1 25 | $358.4M | $79.1M | ||
| Q4 24 | $411.3M | $71.8M | ||
| Q3 24 | $396.9M | $54.1M | ||
| Q2 24 | $360.1M | $42.1M | ||
| Q1 24 | $325.9M | $48.4M |
总债务APLSSRI
| Q4 25 | — | $180.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSRI
| Q4 25 | $370.1M | $179.8M | ||
| Q3 25 | $401.2M | $251.2M | ||
| Q2 25 | $156.3M | $260.5M | ||
| Q1 25 | $164.2M | $253.1M | ||
| Q4 24 | $228.5M | $245.3M | ||
| Q3 24 | $237.1M | $271.4M | ||
| Q2 24 | $264.3M | $270.5M | ||
| Q1 24 | $266.7M | $277.3M |
总资产APLSSRI
| Q4 25 | $1.1B | $551.2M | ||
| Q3 25 | $1.1B | $632.1M | ||
| Q2 25 | $821.4M | $639.4M | ||
| Q1 25 | $807.3M | $657.4M | ||
| Q4 24 | $885.1M | $621.6M | ||
| Q3 24 | $901.9M | $662.5M | ||
| Q2 24 | $904.5M | $666.7M | ||
| Q1 24 | $831.9M | $675.4M |
负债/权益比APLSSRI
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $8.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $2.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 1.3% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $12.2M |
8季度趋势，按日历期对齐
经营现金流APLSSRI
| Q4 25 | $-14.2M | $8.8M | ||
| Q3 25 | $108.5M | $3.6M | ||
| Q2 25 | $4.4M | $10.7M | ||
| Q1 25 | $-53.4M | $10.9M | ||
| Q4 24 | $19.4M | $19.2M | ||
| Q3 24 | $34.1M | $10.8M | ||
| Q2 24 | $-8.3M | $8.7M | ||
| Q1 24 | $-133.0M | $9.1M |
自由现金流APLSSRI
| Q4 25 | $-14.3M | $2.6M | ||
| Q3 25 | $108.3M | $-2.7M | ||
| Q2 25 | $4.4M | $7.4M | ||
| Q1 25 | $-53.4M | $4.8M | ||
| Q4 24 | $19.3M | $14.0M | ||
| Q3 24 | — | $4.6M | ||
| Q2 24 | $-8.4M | $1.5M | ||
| Q1 24 | $-133.3M | $3.3M |
自由现金流率APLSSRI
| Q4 25 | -7.1% | 1.3% | ||
| Q3 25 | 23.6% | -1.3% | ||
| Q2 25 | 2.5% | 3.3% | ||
| Q1 25 | -32.0% | 2.2% | ||
| Q4 24 | 9.1% | 6.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | -4.2% | 0.6% | ||
| Q1 24 | -77.3% | 1.4% |
资本支出强度APLSSRI
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 2.9% | ||
| Q2 24 | 0.0% | 3.0% | ||
| Q1 24 | 0.2% | 2.4% |
现金转化率APLSSRI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
